TNFRSF10A and non-Hodgkin lymphoma: Another CR was achieved using the combination of the DR4 agonist mapatumumab, paclitaxel, and carboplatin for NSCLC [126], and a CR was observed in a single-agent trial using mapatumumab for the treatment of NHL [23].